Boehringer planning job cuts in Germany | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Germany's Boehringer Ingelheim has implemented a hiring freeze and plans to reduce its headcount in its home market in a bid to reduce costs.


The news was revealed in German newspaper Frankfurter Allgemeine Zeitung, which cited a company spokesperson who said Boehringer wants to trim its costs by 15 per cent in order to make more money available for investments.


The news also comes shortly after the company agreed a $650m settlement of all state and federal litigation in the US regarding its oral anticoagulant Pradaxa (dabigatran), which focused on the drug's safety.


"We have to create scope for further development, which will enable us to continue to invest vigorously in organic and sustainable growth," said Boehringer's chairman Andreas Barner.